Association Between AMH Levels and Fertility/Reproductive Outcomes Among Women Undergoing IVF: A Retrospective Study.

Area of Science:

• Reproductive Endocrinology
• In Vitro Fertilization (IVF)
• Reproductive Medicine

Background:

• Anti-Müllerian Hormone (AMH) is a key biomarker for predicting ovarian response to gonadotropin stimulation.
• AMH plays a critical role in the recruitment of ovarian primordial follicles and the selection of dominant follicles.

Purpose of the Study:

• To evaluate serum AMH levels in women undergoing IVF.
• To assess the association between AMH levels and fertility/reproductive outcomes in IVF patients.

Main Methods:

• A retrospective study included 665 women undergoing IVF.
• Participants were categorized into groups based on AMH levels (≥1.1 and ≤1.1).
• Data collected included age, LH, FSH, oocytes retrieved, and fertilization rates; statistical analyses (t-test, chi-square) were performed.

Main Results:

• Women with AMH ≥1.1 showed significantly higher counts of retrieved oocytes, mature oocytes, fertilized oocytes, and cleaved embryos (p<0.001).
• While not statistically significant, embryo transfer, fertilization, and clinical pregnancy rates were slightly higher in the AMH ≥1.1 group.
• A higher live birth rate was observed in the AMH ≥1.1 group (25.85% vs. 22.22%).

Conclusions:

• Elevated serum AMH levels (≥1.10) are associated with a greater number of retrieved oocytes and improved oocyte quality.
• Higher AMH levels correlate with increased rates of embryo transfer and fertilization.
• AMH serves as a significant predictor for enhanced fertility outcomes in women undergoing IVF.